Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 24;14:2868. doi: 10.1038/s41467-023-38526-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — a Illustration of neural crest pro-inflammatory activation using neural crest explants and LPS + ATP treatment. Xenopus illustrations © Natalya Zahn (2022). b Average percentage of cdh1 promoter methylation in neural crest explants from wild type and LPS + ATP conditions (N = 3 explants pools per group, n = 10 explants per point). cdh1 promoter methylation is significantly increased by ~15% in LPS + ATP treated samples in comparison to controls (p = 0.0164, two-sided Welch’s t test). Data are presented as mean values and minimum to maxima. c Average percentage of CDH1 promoter methylation in hiNCCs under wild type (WT), TNFa, ECAD KO or ECAD KO + TNFa conditions, showing significant CDH1 promoter methylation in TNFa exposed hiNCCs (n = 7 per group; p = 0.0048) and ECAD KO + LPS + ATP in comparison to ECAD KO (p = 0.0002). Two-way ANOVA. d Illustration of dCas9-DNMT3A-GFP system. e Average percentage of cdh1 promoter methylation in neural crest explants from control (non-injected, N = 6), dCas9-DNMT3A-GFP (N = 5) and dCas9-DNMT3A-GFP + sgRNA (N = 5) injected embryos. cdh1 promoter methylation is increased in dCas9-DNMT3A-GFP + sgRNA injected neural crest in comparison to controls (p = 0.0035, Two-way ANOVA). f cdh1 levels in the neural crest from control, dCas9-DNMT3A-GFP and dCas9-DNMT3A-GFP + sgRNA injected embryos, with reduction in dCas9-DNMT3A-GFP + sgRNA in comparison to controls (p = 0.009). N = 4 per group, pool of neural crest explants n = 10 per point. Two-way ANOVA. g twist ISH in Xenopus embryos displaying neural crest migration in control, dCas9-DNMT3A-GFP and dCas9-DNMT3A-GFP + sgRNA injected embryos. Neural crest migration is evidenced by black brackets. h Neural crest migration quantification in control, dCas9-DNMT3A-GFP and dCas9-DNMT3A-GFP + sgRNA injected embryos, showing reduction in dCas9-DNMT3A-GFP + sgRNA in comparison to controls (p = 0.002). n = 9 per group, Two-way ANOVA. Boxplots centre is the median, with bounds representing the 25th and 75th percentile, with and whiskers as minima to maxima. Source data are provided as a Source Data file. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001.